Nedunjelian A, Ng C, Lim P, Sulaiman A, Koh O, Francis B
Neuropsychiatr Dis Treat. 2025; 21:465-475.
PMID: 40070368
PMC: 11893478.
DOI: 10.2147/NDT.S494458.
Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S
J Patient Rep Outcomes. 2023; 7(1):122.
PMID: 38015301
PMC: 10684842.
DOI: 10.1186/s41687-023-00658-9.
Baminiwatta A, Correll C
Front Psychiatry. 2023; 14:1194222.
PMID: 37333928
PMC: 10272363.
DOI: 10.3389/fpsyt.2023.1194222.
Amerika W, van der Gaag S, Mosch A, Van Der Gaag N, Hoffmann C, Zutt R
Mov Disord Clin Pract. 2022; 9(5):676-687.
PMID: 35844282
PMC: 9274355.
DOI: 10.1002/mdc3.13463.
Elefante C, Brancati G, Torrigiani S, Amadori S, Ricciardulli S, Pistolesi G
Curr Neuropharmacol. 2022; 21(12):2516-2542.
PMID: 35794767
PMC: 10616925.
DOI: 10.2174/1570159X20666220706110157.
Treatable Hyperkinetic Movement Disorders Not to Be Missed.
Meneret A, Garcin B, Frismand S, Lannuzel A, Mariani L, Roze E
Front Neurol. 2021; 12:659805.
PMID: 34925200
PMC: 8671871.
DOI: 10.3389/fneur.2021.659805.
Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.
Patel R, Mansuri Z, Chopra A
Heliyon. 2019; 5(5):e01745.
PMID: 31193370
PMC: 6526243.
DOI: 10.1016/j.heliyon.2019.e01745.
Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.
Estevez-Fraga C, Zeun P, Lopez-Sendon Moreno J
Drugs Aging. 2018; 35(11):959-971.
PMID: 30357723
DOI: 10.1007/s40266-018-0590-y.
Cholinergic medication for antipsychotic-induced tardive dyskinesia.
Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H
Cochrane Database Syst Rev. 2018; 3:CD000207.
PMID: 29553158
PMC: 6494194.
DOI: 10.1002/14651858.CD000207.pub2.
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.
Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H
Cochrane Database Syst Rev. 2018; 3:CD000208.
PMID: 29552749
PMC: 6494382.
DOI: 10.1002/14651858.CD000208.pub2.
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
Bergman H, Rathbone J, Agarwal V, Soares-Weiser K
Cochrane Database Syst Rev. 2018; 2:CD000459.
PMID: 29409162
PMC: 6491084.
DOI: 10.1002/14651858.CD000459.pub3.
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
El-Sayeh H, Rathbone J, Soares-Weiser K, Bergman H
Cochrane Database Syst Rev. 2018; 1:CD000458.
PMID: 29342497
PMC: 6491120.
DOI: 10.1002/14651858.CD000458.pub3.
Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Bergman H, Soares-Weiser K
Cochrane Database Syst Rev. 2018; 1:CD000204.
PMID: 29341071
PMC: 6491293.
DOI: 10.1002/14651858.CD000204.pub2.
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.
Peroza L, Schaffer L, de Freitas C, Leal C, Ferrari M, Duarte M
Neurochem Res. 2016; 41(9):2481-9.
PMID: 27230882
DOI: 10.1007/s11064-016-1961-6.
Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.
Zutshi D, Cloud L, Factor S
Tremor Other Hyperkinet Mov (N Y). 2014; 4:266.
PMID: 25374768
PMC: 4219112.
DOI: 10.7916/D8MS3R8C.
Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.
Kim J, MacMaster E, Schwartz T
Drugs Context. 2014; 3:212259.
PMID: 24744806
PMC: 3989508.
DOI: 10.7573/dic.212259.
Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?.
Koola M, Tsapakis E, Wright P, Smith S, Kerwin Rip R, Nugent K
J Psychopharmacol. 2014; 28(7):665-70.
PMID: 24595968
PMC: 5950711.
DOI: 10.1177/0269881114523861.
Tardive dyskinesia: therapeutic options for an increasingly common disorder.
Cloud L, Zutshi D, Factor S
Neurotherapeutics. 2013; 11(1):166-76.
PMID: 24310603
PMC: 3899488.
DOI: 10.1007/s13311-013-0222-5.
Tardive and spontaneous dyskinesia incidence in the general population.
Merrill R, Lyon J, Matiaco P
BMC Psychiatry. 2013; 13:152.
PMID: 23714238
PMC: 3681708.
DOI: 10.1186/1471-244X-13-152.
No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients.
Kim I, Yoon H, Kang S, Park Y, Kim Y, Kim S
Psychiatry Investig. 2012; 9(2):191-4.
PMID: 22707972
PMC: 3372569.
DOI: 10.4306/pi.2012.9.2.191.